EX-99.1 2 d287649dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

Imperva Announces Third Quarter 2016 Financial Results

 

    Total revenue of $68.4 million

 

    Services revenue growth of 40% was driven by the 82% year-over-year increase in subscription revenue

 

    Short-term deferred revenue increased 36% year-over-year

 

    Concludes review of strategic alternatives

 

    Implements restructuring initiative to accelerate growth and profitability

Redwood Shores, Calif. – November 3, 2016Imperva, Inc. (NYSE: IMPV), committed to protecting business-critical data and applications in the cloud and on-premises, today announced financial results for the third quarter ended September 30, 2016.

“We are pleased with our third quarter performance, particularly our ability to exceed revenue and profitability guidance,” stated Anthony Bettencourt, President and Chief Executive Officer of Imperva. “During the quarter, we benefitted from the ongoing momentum of subscription revenue driven by our Incapsula business, as well as overall cost controls. We are confident in our ability to reaccelerate growth given the ongoing need for enterprises to protect their business-critical data and applications supported by our best-of-breed discovery, protection and compliance solutions.”

Third Quarter 2016 Financial Highlights

 

    Revenue: Total revenue for the third quarter of 2016 was $68.4 million compared to $63.3 million in the third quarter of 2015. Within total revenue, product revenue was $22.5 million, compared to $30.5 million in the same period last year. Services revenue increased 40% year-over-year to $45.9 million and accounted for 67% of total revenue. Within services revenue, overall subscription revenue grew 82% to $22.4 million, compared to the third quarter of 2015. Combined product and subscription revenue was $44.9 million, compared to $42.7 million in the third quarter of 2015.

 

    Operating Profit (Loss): Operating loss was $(11.8) million for the third quarter compared to a loss of $(5.3) million during the third quarter in 2015. The results as reported in accordance with U.S. generally accepted accounting principles (GAAP) included stock-based compensation, amortization of purchased intangibles and costs associated with the review of strategic alternatives and non-routine stockholder matters of $14.3 million for the third quarter of 2016 and stock-based compensation and amortization of purchased intangibles of $12.0 million for the third quarter of 2015. Non-GAAP operating income for the third quarter was $2.5 million, compared to operating income of $6.7 million during the same period in 2015, excluding the above mentioned charges.

 

    Net Profit (Loss): Net loss for the third quarter was $(11.7) million, or $(0.36) per share based on 32.4 million weighted average shares outstanding. This compares to net loss of $(5.7) million, or $(0.19) per share based on 30.8 million weighted average shares outstanding in the third quarter of 2015.


Non-GAAP net income for the third quarter of 2016 was $2.5 million, or $0.08 per share based on 33.1 million weighted average diluted shares outstanding, excluding the above mentioned charges. This compares to non-GAAP net income of $6.3 million, or $0.19 per share based on 32.7 million weighted average diluted shares outstanding in the third quarter of 2015.

 

    Balance Sheet and Cash Flow: As of September 30, 2016, Imperva had cash, cash equivalents and investments of $259.0 million. Total deferred revenue of $116.6 million increased 28% compared to $91.3 million as of September 30, 2015. Short-term deferred revenue of $90.4 million increased 36% compared to $66.3 million as of September 30, 2015.

The company generated $9.8 million in net cash from operations for the third quarter of 2016, compared with generating $10.5 million in the third quarter of 2015. The company generated $4.2 million in free cash flow (cash flows from operating activities, less capital expenditures) for the quarter compared to generating $9.3 million during the third quarter of 2015.

A reconciliation of GAAP to non-GAAP financial measures has been provided in the financial statement tables included in this press release. An explanation of these measures is also included below under the heading “Non-GAAP Financial Measures.”

Third Quarter and Recent Operating Highlights

 

    During the third quarter of 2016, Imperva booked 137 deals with a value over $100,000, compared to 130 in the third quarter of 2015.

 

    During the third quarter of 2016, Imperva added 209 new customers compared to 188 during the third quarter of 2015. Imperva now has over 5,000 customers in more than 100 countries around the world.

 

    Imperva announced its first cloud point of presence (POP) using Amazon Web Services dedicated to storing Imperva Skyfence customers’ cloud application data within the European Union (EU).

 

    Imperva announced that Imperva SecureSphere was selected for the Department of Homeland Security’s continuous diagnostics and migration program.

 

    Imperva introduced a revamped Imperva PartnerSphere Channel Program to help more than 250 global channel partners build a high growth, profitable and differentiated cyber security business with Imperva products.

Conclusion of Strategic Alternatives Review Process

Imperva announced today that its Board of Directors has concluded its previously announced review of strategic alternatives to enhance shareholder value. The Board, with the assistance of financial advisors, conducted a thorough assessment of options to maximize shareholder value and determined that continuing to grow Imperva as a standalone company provides the best means for creating value and is in the best interests of stockholders.


“After evaluating the full range of potential alternatives, the Board concluded that the continued execution of our business plan, with some modification, is the best path to enhance shareholder value,” said Mr. Bettencourt. “We are confident that our proven products and solutions will remain fundamental tools for companies around the world looking to protect their critical data and applications. We are taking aggressive actions to better position Imperva to compete and win in the evolving marketplace and our third quarter results demonstrate our long-term growth potential.”

Restructuring Initiative

The company also announced it is implementing a restructuring initiative to bolster Imperva’s profitability and competitiveness by reducing sales, marketing and general and administrative expenses through reductions in headcount and spending. Imperva expects these efforts will result in an estimated annual savings of $15 million and anticipates they will be completed by the end of the quarter.

“We believe these initiatives will enable us to maintain our growth and drive profitability by sharpening our operational focus, enhancing our position in the most attractive market areas and establishing a more cost-efficient structure that preserves our ability to invest in our core solutions,” added Mr. Bettencourt. “We believe these are the right next steps, allowing us to build on our strengths and deliver lasting value to our shareholders and customers.”

Business Outlook

The following forward-looking statements reflect expectations as of November 3, 2016. Results may be materially different and could be affected by the factors detailed in this press release and in recent Imperva SEC filings.

Fourth Quarter Expectations – Ending December 31, 2016

Imperva expects total revenue for the fourth quarter of 2016 to be in the range of $69.0 million to $71.0 million. The company expects in the fourth quarter of 2016 non-GAAP gross margins of approximately 81%. Further, Imperva expects in the fourth quarter of 2016 non-GAAP operating income to be in the range of $0.9 million to $2.0 million and non-GAAP net income to be in the range of $0.3 million to $1.4 million, or $0.01 to $0.04 per share based on approximately 35.0 million weighted average shares, which excludes stock-based compensation and amortization of purchased intangibles.

Full Year Expectations –Ending December 31, 2016

Imperva expects total revenue for 2016 to be in the range of $255.1 million to $257.1 million. Imperva expects 2016 non-GAAP gross margins of approximately 81%. Further, the company expects 2016 non-GAAP operating loss to be in the range of $(11.1) million to $(10.0) million and non-GAAP net loss to be in the range of $(12.4) million to $(11.3) million, or $(0.38) to $(0.35) per share based on approximately 33.0 million weighted average shares, which excludes stock-based compensation and amortization of purchased intangibles. Imperva expects capital expenditures for the full year to be in the range of $18.0 million to $20.0 million. Finally, the company expects to generate positive cash flows from operations in 2016.


No reconciliation of forward-looking GAAP to non-GAAP financial measures has been provided in this press release. An explanation is included below under the heading “Non GAAP Financial Measures.”

Quarterly Conference Call

Imperva will host a conference call today at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to review the company’s financial results for the third quarter ended September 30, 2016. To access this call, dial (800) 776-0487 for the U.S. or Canada or (913) 981-5519 for international callers with conference ID #1971363. A live webcast of the conference call will be accessible from the investors page of the Imperva website at www.imperva.com, and a recording will be archived and accessible at www.imperva.com. An audio replay of this conference call will also be available through November 17, 2016, by dialing (877) 870-5176 for the U.S. and Canada, or (858) 384-5517 for international callers and entering passcode #1971363.

Non-GAAP Financial Measures

Imperva reports all financial information required in accordance with U.S. generally accepted accounting principles (GAAP). To supplement the Imperva unaudited condensed consolidated financial statements presented in accordance with GAAP, Imperva uses certain non-GAAP measures of financial performance. The presentation of these non-GAAP financial measures is not intended to be considered in isolation from, as a substitute for, or superior to, the financial information prepared and presented in accordance with GAAP, and may be different from non-GAAP financial measures used by other companies. In addition, these non-GAAP measures have limitations in that they do not reflect all of the amounts associated with the results of Imperva operations as determined in accordance with GAAP. The non-GAAP financial measures used by Imperva include historical and forward-looking non-GAAP operating income (loss), non-GAAP net income (loss) and non-GAAP basic and diluted loss per share and forward-looking non-GAAP gross margin. These non-GAAP financial measures exclude stock-based compensation, amortization of purchased intangibles, and costs associated with the review of strategic alternatives and non-routine stockholder matters from the Imperva unaudited condensed consolidated statement of operations.

For a description of these items, including the reasons why management adjusts for them, and reconciliations of historical non-GAAP financial measures to the most directly comparable GAAP financial measures, please see the section of the accompanying tables titled “Use of Non-GAAP Financial Information” as well as the related tables that precede it. Imperva may consider whether other significant non-recurring items that arise in the future should also be excluded in calculating the non-GAAP financial measures it uses.

Imperva believes that these non-GAAP financial measures, when taken together with the corresponding GAAP financial measures, provide meaningful supplemental information regarding the performance of Imperva by excluding certain items that may not be indicative of the company’s core business, operating results or future outlook. Imperva management uses, and believes that investors benefit from referring to, these non-GAAP financial measures in assessing operating results of Imperva, as well as when planning, forecasting and analyzing future periods. These non-GAAP financial measures also facilitate comparisons of the performance of Imperva to prior periods.


Imperva does not provide a reconciliation of forward-looking non-GAAP financial measures to their comparable GAAP financial measures because it could not do so without unreasonable effort due to unavailability of information needed to calculate reconciling items and due to variability, complexity and limited visibility of the adjusting items that would be excluded from the non-GAAP financial measures in future periods. When planning, forecasting and analyzing future periods, Imperva does so primarily on a non-GAAP basis without preparing a GAAP analysis as that would require estimates for various cash and non-cash reconciling items that would be difficult to predict with reasonable accuracy. In particular, stock-based compensation expense would be difficult to estimate because it depends on the company’s future hiring and retention needs, as well as the future fair market value of the company’s common stock, all of which are difficult to predict and subject to constant change. In addition, for purposes of setting annual guidance, it would be difficult to quantify stock-based compensation expense for the year with reasonable accuracy in the current quarter. As a result, the company does not believe that a GAAP reconciliation would provide meaningful supplemental information about the company’s outlook.

Forward Looking Statements

This press release contains forward-looking statements, including without limitation those regarding the Imperva “Business Outlook” (“Fourth Quarter Expectations – Ending December 31, 2016” and “Full Year Expectations – Ending December 31, 2016”); the company’s beliefs that strength in its subscription revenues and momentum in its Incapsula business will continue; the company’s belief that it will be able to reaccelerate growth over the longer term; the company’s belief that it will continue to have best-of-breed discovery, protection and compliance solutions; the company’s plans to grow as a standalone company and deliver value to stockholders and customers; the restructuring initiative and its anticipated benefits; and all related statements. These forward-looking statements are subject to material risks and uncertainties that may cause actual results to differ substantially from expectations. Investors should consider important risk factors, which include: demand for the company’s cyber security solutions may not increase or may decrease, including as a result of global macroeconomic conditions and other economic conditions that may reduce enterprise software or security spending generally or customer perceptions about the necessity or reliability of solutions such as ours; the company’s sales expectations for large customers may not materialize in a particular quarter or at all; the company may not timely introduce new products or services or versions of its products or services and such products or services may not be accepted by the market or may have defects, errors, outages or failures; competitors may be perceived by customers to offer greater value or to be better positioned to help handle cyber security threats and protect their businesses from major risk; existing customers may focus their additional cyber security spending on other technologies or addressing other risks; the company’s growth may be lower than anticipated; the markets that the company addresses may not grow as anticipated; the company may not be able to achieve the anticipated operational efficiencies and other benefits of the restructuring initative; and the risk that the announcement that the board has concluded its review of strategic alternatives may create uncertainty about the company’s prospects as a stand-alone entity and lead to the perception of a change in the direction of its business or other instability, irrespective of the actual circumstances, which may be exploited by competitors, cause concern to current or potential customers and partners, and make it more difficult to attract and retain qualified personnel; and other risks detailed under the caption “Risk Factors” in the company’s Form 10-Q filed with the Securities and Exchange Commission, or the SEC, on August 5, 2016 and the company’s other SEC filings. You can obtain copies of the company’s SEC filings on the SEC’s website at www.sec.gov.


The foregoing information represents the company’s outlook only as of the date of this press release, and Imperva undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, new developments or otherwise.

About Imperva

Imperva® (NYSE:IMPV) is a leading provider of cyber security solutions that protect business-critical data and applications. The company’s SecureSphere, CounterBreach, Incapsula and Skyfence product lines enable organizations to discover assets and risks, protect information wherever it lives – in the cloud and on-premises – and comply with regulations. The Imperva Defense Center, a research team comprised of some of the world’s leading experts in data and application security, continually enhances Imperva products with up-to-the minute threat intelligence, and publishes reports that provide insight and guidance on the latest threats and how to mitigate them. Imperva is headquartered in Redwood Shores, California. Learn more: www.imperva.com, our blog, on Twitter.

© 2016 Imperva, Inc. All rights reserved. Imperva, the Imperva logo, SecureSphere, CounterBreach, Incapsula and Skyfence are trademarks of Imperva, Inc. and its subsidiaries.

###


IMPERVA, INC. AND SUBSIDIARIES

Consolidated Statements of Operations

(On a GAAP basis)

(In thousands, except per share data)

(Unaudited)

 

     Three months ended
September 30,
    Nine months ended
September 30,
 
     2016     2015     2016     2015  

Net revenue:

        

Products and license

   $ 22,486      $ 30,451      $ 58,157      $ 71,450   

Services

     45,921        32,898        127,896        90,134   
  

 

 

   

 

 

   

 

 

   

 

 

 

Total net revenue

     68,407        63,349        186,053        161,584   

Cost of revenue(1):

        

Products and license

     2,394        2,741        6,392        7,535   

Services

     11,354        9,148        32,841        26,250   
  

 

 

   

 

 

   

 

 

   

 

 

 

Total cost of revenue

     13,748        11,889        39,233        33,785   
  

 

 

   

 

 

   

 

 

   

 

 

 

Gross profit

     54,659        51,460        146,820        127,799   

Operating expenses:

        

Research and development

     15,289        13,183        46,884        38,973   

Sales and marketing

     38,128        31,806        119,845        97,130   

General and administrative (2), (3)

     12,669        11,401        38,800        32,781   

Amortization of acquired intangible assets

     352        352        1,056        1,056   
  

 

 

   

 

 

   

 

 

   

 

 

 

Total operating expenses

     66,438        56,742        206,585        169,940   
  

 

 

   

 

 

   

 

 

   

 

 

 

Loss from operations

     (11,779     (5,282     (59,765     (42,141

Other income (expense), net

     107        91        (51     (213
  

 

 

   

 

 

   

 

 

   

 

 

 

Loss before provision for income taxes

     (11,672     (5,191     (59,816     (42,354

Provision for income taxes

     66        556        645        747   
  

 

 

   

 

 

   

 

 

   

 

 

 

Net loss

   $ (11,738   $ (5,747   $ (60,461   $ (43,101
  

 

 

   

 

 

   

 

 

   

 

 

 

Net loss per share of common stock stockholders, basic and diluted

   $ (0.36   $ (0.19   $ (1.88   $ (1.47
  

 

 

   

 

 

   

 

 

   

 

 

 

Shares used in computing net loss per share of common stock, basic and diluted

     32,445        30,797        32,130        29,362   
  

 

 

   

 

 

   

 

 

   

 

 

 

(1) Stock-based compensation expense as included in above:

        

Cost of revenue

     1,079        836        3,604        2,713   

Research and development

     3,380        3,311        11,431        10,122   

Sales and marketing

     4,405        3,314        17,182        12,824   

General and administrative

     4,113        4,201        13,519        13,142   
  

 

 

   

 

 

   

 

 

   

 

 

 

Total stock-based compensation expense

   $ 12,977      $ 11,662      $ 45,736      $ 38,801   
  

 

 

   

 

 

   

 

 

   

 

 

 

(2) Strategic review expense as included in above:

        

General and administrative

     298        0        298        0   
  

 

 

   

 

 

   

 

 

   

 

 

 

Total strategic review expense

   $ 298      $ —        $ 298      $ —     
  

 

 

   

 

 

   

 

 

   

 

 

 

(3) Non-routine stockholder matters expense as included in above:

        

General and administrative

     651        0        651        0   
  

 

 

   

 

 

   

 

 

   

 

 

 

Total non-routine stockholder matters expense

   $ 651      $ —        $ 651      $ —     
  

 

 

   

 

 

   

 

 

   

 

 

 


IMPERVA, INC. AND SUBSIDIARIES

Consolidated Balance Sheets

(In thousands)

(Unaudited)

 

     September 30,
2016
    December 31,
2015
 

ASSETS

    

CURRENT ASSETS:

    

Cash and cash equivalents

   $ 110,017      $ 168,252   

Short-term investments

     149,014        96,555   

Restricted cash

     69        79   

Accounts receivable, net

     45,702        61,051   

Inventory

     775        815   

Prepaid expenses and other current assets

     7,374        7,965   
  

 

 

   

 

 

 

Total current assets

     312,951        334,717   

Property and equipment, net

     20,521        12,164   

Goodwill

     34,972        34,972   

Acquired intangible assets, net

     6,935        7,991   

Severance pay fund

     5,137        4,530   

Restricted cash

     1,665        1,665   

Deferred tax assets

     771        588   

Other assets

     1,244        1,042   
  

 

 

   

 

 

 

TOTAL ASSETS

   $ 384,196      $ 397,669   
  

 

 

   

 

 

 

LIABILITIES AND STOCKHOLDERS’ EQUITY

    

CURRENT LIABILITIES:

    

Accounts payable

   $ 4,559      $ 6,870   

Accrued compensation and benefits

     21,023        20,259   

Accrued and other current liabilities

     6,438        14,283   

Deferred revenue

     90,449        79,132   
  

 

 

   

 

 

 

Total current liabilities

     122,469        120,544   

Other liabilities

     5,349        4,515   

Deferred revenue

     26,101        27,525   

Accrued severance pay

     5,806        4,884   
  

 

 

   

 

 

 

TOTAL LIABILITIES

     159,725        157,468   
  

 

 

   

 

 

 

STOCKHOLDERS’ EQUITY:

    

Common stock

     3        3   

Additional paid-in capital

     492,238        448,069   

Accumulated deficit

     (267,001     (206,540

Accumulated other comprehensive loss

     (769     (1,331
  

 

 

   

 

 

 

TOTAL STOCKHOLDERS’ EQUITY

     224,471        240,201   
  

 

 

   

 

 

 

TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY

   $ 384,196      $ 397,669   
  

 

 

   

 

 

 


IMPERVA, INC. AND SUBSIDIARIES

Consolidated Statements of Cash Flows

(In thousands)

(Unaudited)

 

     Nine months ended September 30  
     2016     2015  

CASH FLOWS FROM OPERATING ACTIVITIES:

    

Net loss

   $ (60,461   $ (43,101

Adjustments to reconcile net loss to net cash provided by operating activities:

    

Depreciation and amortization

     5,107        3,337   

Stock-based compensation

     45,736        38,801   

Amortization of acquired intangibles

     1,056        1,056   

Loss on disposals of PPE

     267        —     

Amortization of premiums/accretion of discounts on short-term investments

     144        398   

Excess tax deficiencies (benefits) from share-based compensation

     29        (60

Other

     (265     —     

Changes in operating assets and liabilities:

    

Accounts receivable, net

     15,349        5,960   

Inventory

     40        (683

Prepaid expenses and other assets

     549        (1,760

Accounts payable

     (2,089     (964

Accrued compensation and benefits

     (2,360     571   

Accrued and other liabilities

     515        1,187   

Severance pay (net)

     315        356   

Deferred revenue

     9,893        10,116   

Deferred tax assets

     (183     (26
  

 

 

   

 

 

 

Net cash provided by operating activities

     13,642        15,188   
  

 

 

   

 

 

 

CASH FLOWS FROM INVESTING ACTIVITIES:

    

Proceeds from sales/maturities of short-term investments

     54,916        20,721   

Purchase of short-term investments

     (107,403     (75,399

Net purchases of property and equipment

     (13,953     (4,038

Change in restricted cash

     10        (12
  

 

 

   

 

 

 

Net cash used in investing activities

     (66,430     (58,728
  

 

 

   

 

 

 

CASH FLOWS FROM FINANCING ACTIVITIES:

    

Settlement of holdback liability

     (7,157     —     

Proceeds from follow-on public offering, net of offering costs

     —          127,853   

Offering costs relating to follow-on public offering

     (112     —     

Proceeds from issuance of common stock, net of repurchases

     8,106        12,668   

Shares withheld for tax withholding on vesting of restricted stock units

     (6,520     (7,221

Excess tax (deficiencies) benefits from share-based compensation

     (29     60   
  

 

 

   

 

 

 

Net cash (used) provided by financing activities

     (5,712     133,360   
  

 

 

   

 

 

 

Effect of exchange rate changes on cash and cash equivalents

     265        33   
  

 

 

   

 

 

 

NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS

     (58,235     89,853   

CASH AND CASH EQUIVALENTS - Beginning of period

     168,252        68,096   
  

 

 

   

 

 

 

CASH AND CASH EQUIVALENTS - End of period

   $ 110,017      $ 157,949   
  

 

 

   

 

 

 


IMPERVA, INC. AND SUBSIDIARIES

(Reconciliation of GAAP to Non-GAAP Measures)

(In thousands, except per share amounts)

(Unaudited)

 

     Three months ended
September 30,
    Nine months ended
September 30,
 
     2016     2015     2016     2015  

GAAP operating loss

   $ (11,779     (5,282   $ (59,765   $ (42,141

Plus:

        

Stock-based compensation expense

     12,977        11,662        45,736        38,801   

Strategic review expense

     298        —          298        —     

Non-routine stockholder matters expense

     651        —          651        —     

Amortization of purchased intangibles

     352        352        1,056        1,056   
  

 

 

   

 

 

   

 

 

   

 

 

 

Non-GAAP operating income (loss)

   $ 2,499        6,732      $ (12,024   $ (2,284
  

 

 

   

 

 

   

 

 

   

 

 

 

GAAP net loss attributable to Imperva, Inc. stockholders

   $ (11,738     (5,747   $ (60,461   $ (43,101

Plus:

        

Stock-based compensation expense

     12,977        11,662        45,736        38,801   

Strategic review expense

     298        —          298        —     

Non-routine stockholder matters expense

     651        —          651        —     

Amortization of purchased intangibles

     352        352        1,056        1,056   
  

 

 

   

 

 

   

 

 

   

 

 

 

Non-GAAP net income (loss)

   $ 2,540        6,267      $ (12,720   $ (3,244
  

 

 

   

 

 

   

 

 

   

 

 

 

Weighted average shares outstanding, basic

     32,445        30,797        32,130        29,362   

Weighted average shares outstanding, diluted

     33,125        32,733        32,130        29,362   

Non-GAAP net income (loss), basic

   $ 0.08      $ 0.20      $ (0.40   $ (0.11

Non-GAAP net income (loss), diluted

   $ 0.08      $ 0.19      $ (0.40   $ (0.11


IMPERVA, INC. AND SUBSIDIARIES

(Reconciliation of Free Cash Flow)

(In thousands)

(Unaudited)

 

     Nine months ended September 30  
     2016      2015  

Net cash provided by operating activities

   $ 13,642       $ 15,188   

Less:

     

Net purchases of property and equipment

     (13,953      (4,038
  

 

 

    

 

 

 

Total free cash (used) generated

   $ (311    $ 11,150   
  

 

 

    

 

 

 


Use of Non-GAAP Financial Information

In addition to the reasons stated under “Non-GAAP Financial Measures” above, which are generally applicable to each of the items Imperva excludes from its non-GAAP financial measures, Imperva believes it is appropriate to exclude or give effect to certain items for the following reasons:

Stock-Based Compensation: When evaluating the performance of its consolidated results, Imperva does not consider stock-based compensation charges. Likewise, the Imperva management team excludes stock-based compensation expense from its operating plans. In contrast, the Imperva management team is held accountable for cash-based compensation and such amounts are included in its operating plans. Further, when considering the impact of equity award grants, Imperva places a greater emphasis on overall stockholder dilution rather than the accounting charges associated with such grants.

Imperva excludes stock-based compensation expense from its non-GAAP financial measures primarily because it does not consider it part of ongoing operating results when assessing the performance of its business, and the exclusion of the expense facilitates the comparison of results and business outlook for future periods with results for prior periods in order to better understand the long term performance of its business.

Amortization of Purchased Intangibles. When analyzing the operating performance of an acquired entity, Imperva’s management focuses on the total return provided by the investment (i.e., operating profit generated from the acquired entity as compared to the purchase price paid) without taking into consideration any allocations made for accounting purposes. Because the purchase price for an acquisition necessarily reflects the accounting value assigned to intangible assets (including acquired technology and goodwill), when analyzing the operating performance of an acquisition in subsequent periods, Imperva’s management excludes the GAAP impact of acquired intangible assets to its financial results. Imperva believes that such an approach is useful in understanding the long-term return provided by an acquisition and that investors benefit from a supplemental non-GAAP financial measure that excludes the accounting expense associated with acquired intangible assets.

In addition, in accordance with GAAP, Imperva generally recognizes expenses for internally-developed intangible assets as they are incurred until technological feasibility is reached, notwithstanding the potential future benefit such assets may provide. Unlike internally-developed intangible assets, however, and also in accordance with GAAP, Imperva generally capitalizes the cost of acquired intangible assets and recognizes that cost as an expense over the useful lives of the assets acquired (other than goodwill, which is not amortized, as required under GAAP). As a result of their GAAP treatment, there is an inherent lack of comparability between the financial performance of internally-developed intangible assets and acquired intangible assets. Accordingly, Imperva believes it is useful to provide, as a supplement to its GAAP operating results, a non-GAAP financial measure that excludes the amortization of acquired intangibles.

Review of strategic alternatives and non-routine stockholder matters. During the quarter, Imperva incurred professional service fees and costs related to its review of strategic alternatives and other non-routine stockholder matters. Imperva has excluded the expenses associated with these activities from its non-GAAP financial measures because they are not representative of ongoing operating costs and Imperva does not consider them part of its ongoing operating costs. The exclusion of these expenses facilitates the comparison of results and business outlook for future periods with results for prior periods in order to better understand the long term performance of its business.


Investor Relations Contact Information

Kim Janssen

650.832.6897

kim.janssen@imperva.com

Seth Potter

646.277.1230

IR@imperva.com

Seth.Potter@icrinc.com